Warsaw, Indiana-based WishBone Medical, Inc., a pediatric orthopedic company, has confirmed a deal with Vizient, Inc. to provide orthopedic implants to pediatric patients.
At its core, WishBone Medical focuses on pediatric orthopedic needs. It currently offers 42 pediatric orthopedic product systems. Per the national agreement, Wishbone Medical will provide “anatomically appropriate orthopedic solutions for arms, legs, spine, elbows, wrists and clavicles to surgeons caring for children.”
The Wishbone Medical team is excited about the agreement and its ability to meet the needs of pediatric orthopedic patients. Wishbone Medical Founder, Chairman of the Board, and CEO Nick Deeter said, “In the year 2020, there is still a huge technology deficit in the OR [operating room] with 95% of children receiving adult implants not cleared by the FDA for pediatric use. In some instances, these off-label applications can cause more harm than good.”
Deeter continued, “WishBone is thrilled about another game-changing opportunity to create greater access to solutions that are truly designed around the unmet needs of kids.”
The opportunity appears significant. Vizient is the “largest member-driven, health care performance improvement company in the country.” Its membership base includes more than 50% of acute care providers in the United States. According to the press release, this includes 95% of the nation’s academic medical centers and more than 20% of ambulatory providers.
WishBone Medical provides “implants, instruments, and biologics in sterile packed, single-use procedure kits.” The single-use kits are designed to reduce sterility issues and streamline the operating room process. Per the press release, the single-use model is “crucial” to making the products immediately accessible to Vizient member hospitals and surgery centers.
WishBone Medical Chief Revenue Officer Kevin Blue said, “As surgeons take on a surge of cases post-COVID-19 pandemic, the need for single-use, sterile packed procedure kits has become increasingly apparent.”
Blue continued, “The timing of this partnership could not be more serendipitous.”
